FDA Review Times

T-PEMD-96-9: Published: May 2, 1996. Publicly Released: May 2, 1996.

Additional Materials:

Contact:

Office of Public Affairs
(202) 512-4800
youngc1@gao.gov

GAO examined the Food and Drug Administration's (FDA) drug review and approval times, focusing on: (1) whether the timeliness of new drug reviews and approvals has changed; and (2) how approval times in the United States compare with those in the United Kingdom (UK). GAO found that: (1) new drug applications (NDA) are moving more quickly through the review and approval process; (2) the time taken for NDA approvals has decreased from 33 months in 1987 to 19 months in 1992; (3) the priority FDA assigns to NDA and the experience of application sponsors affect the timeliness of NDA decisions; (4) FDA assigns priority status to those applications expected to provide greater therapeutic relief; (5) NDA are approved 10 months faster than standard applications; (6) FDA made timely decisions on 67 percent of NDA between 1987 and 1993; (7) the on-time percentage for NDA is relatively stable and varies between a low of 62 percent to a high of 72 percent; (8) there is little relationship between the time FDA takes to reach a final decision and whether or not it meets a specific action deadline; (9) sponsors account for 20 percent of the time in NDA approval; (10) UK approval times are similar to the United States' and average 56 working days; (11) UK granted licenses for applications representing 32 new active substances during the 12-month period examined; and (13) it is too early to determine whether the European Union's new method of drug approval will ensure more efficient review while ensuring product safety.

Oct 20, 2017

Oct 2, 2017

  • auditing icon, source: PhotoDisc

    U.S. Territories:

    Public Debt Outlook
    GAO-18-160: Published: Oct 2, 2017. Publicly Released: Oct 2, 2017.

Sep 26, 2017

Jul 13, 2017

Jul 12, 2017

Jun 30, 2017

Jun 29, 2017

Jun 14, 2017

Jun 13, 2017

Looking for more? Browse all our products here